Georgiamune Inc. has gained FDA clearance for its IND application for GIM-531, a first-in-class oral regulatory T cell (Treg) inhibitor that enables the restoration of a strong immune response against cancer.
A group of scientists from Basel University Hospital have designed an antibody-drug conjugate (ADC) that eliminated blood cancer cells without attacking healthy hematopoietic stem cells (HSCs), which they modified by base editing and transplanted to renew an altered blood system. They achieved this by focusing on the panhematopoietic marker CD45.
Scientists at Hansoh Bio LLC, Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising HER3 (erbB3)-targeting antibodies linked to a cytotoxic drug through a linker.
Bispecific T-cell-engaging antibodies have emerged as therapeutic options for the treatment of cancer, but limitations such as short half-life remain to be addressed. Researchers from Biontech SE reported the preclinical pharmacology and efficacy of BNT-142, a bispecific antibody targeting claudin-6 (CLDN6) and the T-cell marker CD3.
Merck Sharp & Dohme LLC has described antibody-drug conjugates (ADCs) comprising antibodies targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) linked to exatecan through a linker reported to be useful for the treatment of cancer.
Scientists at the Institute of Cancer Research have generated a proteolysis targeting chimera (PROTAC) that successfully destroyed RIPK1 in cancer cells.
Achilles Therapeutics plc has established a research collaboration with Arcturus Therapeutics Holdings Inc. to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines targeting clonal neoantigens.
Researchers from Iomx Therapeutics AG presented the discovery and preclinical evaluation of IOMX-0675, a novel LILRB1 and LILRB2 cross-specific antibody being developed for the treatment of solid tumors.
Genmab A/S, in collaboration with Biontech SE, has presented data on a novel OX40 agonist antibody –Hexabody-OX40 (GEN-1055/BNT-315), developed using Genmab’s proprietary Hexabody platform, which promotes the formation of antibody hexamers upon target binding to cell surfaces.
RSS
